Peter J Brown Is Appointed President of Reverba

Reverba, a leading global patient engagement company, today announced the appointment of Peter J. Brown, MBA, as President. He brings more than 20 years of experience in life sciences, healthcare and patient engagement, with a track record of driving growth in highly complex, competitive markets and successfully scaling organizations to support expanding service and product offerings.

“We are delighted to welcome Peter to Reverba. His experience enhances the leadership team and strengthens our ability to transform the way biopharmaceutical companies think and function by incorporating compliant, patient-centered action at the core of their business,” said Cheryl Lubbert, CEO and co-founder of Reverba. “Peter brings the ideal skills we need to accelerate our growth and deliver value for healthcare organizations and patients.”

Peter J Brown joins Reverba at an exciting time, as the company is expanding its proprietary, compliant patient engagement solutions and services to connect biopharma companies with patients to amplify the impact of patient voices.

“I am excited to take on this role at Reverba, a foundational company that helped create the patient engagement space,” said Peter J Brown, President of Reverba. “I see an extraordinary opportunity for Reverba to expand the company’s offerings, built on deep understanding of secure technology solutions that enable meaningful connections with patients.”

Brown joins Reverba from his role as President, Chief Executive Officer and General Manager of Thornberry, provider of hospice and home health software solutions, where he drove market strategy, product development, operations and sales against aggressive financial and operational performance targets, leading two major platform technology initiatives and significant product enhancements. Concurrently, he was Founder and President of Proinligo Consulting, providing support to payers, providers and health systems for digital health services and engagement. He is a Fellow of the Academy for Healthcare Management and holds a Bachelor of Economics from Union College and an MBA in Management from McDonough School of Business, Georgetown University.

SourceReverba

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.